High-dose melphalan and autologous stem cell transplantation for AL amyloidosis: Recent trends in treatment-related mortality and 1-year survival at a single institution

Amyloid

Volumn 18, Issue SUPPL. 1, 2011, Pages 127-129

  Seldin, D C ^a   Andrea, N ^a   Berenbaum, I ^a   Berk, J L ^a   Connors, L ^a   Dember, L M ^a   Doros, G ^a   Fennessey, S ^a   Finn, K ^a   Girnius, S ^a   Lerner, A ^a   Libbey, C ^a   Meier Ewert, H K ^a   O'Connell, R ^a   O'Hara, C ^a   Quillen, K ^a   Ruberg, F L ^a   Sam, F ^a   Segal, A ^a   Shelton, A ^a   Skinner, M ^a   Sloan, J M ^a   Wiesman, J F ^a   Sanchorawala, V ^a   more..

^a BOSTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MELPHALAN;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; DRUG EFFICACY; DRUG MEGADOSE; EVENT FREE SURVIVAL; FOLLOW UP; GASTROINTESTINAL MOTILITY DISORDER; HEART FAILURE; HUMAN; INFORMED CONSENT; INTESTINE ULCER; KIDNEY DYSFUNCTION; LIGHT CHAIN AMYLOIDOSIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PANCYTOPENIA; PATIENT SELECTION; PERICARDIAL EFFUSION; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THERAPY EFFECT; UREMIA;

EID: 79959944848     PISSN: 13506129     EISSN: 17442818     Source Type: Journal    
DOI: 10.3109/13506129.2011.574354     Document Type: Article

References (7)

1. Dember LM, Sanchorawala V, Seldin DC, Wright DG, Lavalley M, Berk JL, Falk RH, Skinner M. Effect of doseintensive intravenous melphalan and autologous blood stemcell transplantation on al amyloidosis-associated renal disease. Ann Intern Med 2001;134:746-753. (Pubitemid 32402067)
2. Seldin DC, Anderson JJ, Sanchorawala V, Malek K, Wright DG, Quillen K, Finn KT, Berk JL, Dember LM, Falk RH, et al. Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. Blood 2004;104:1888-1893. (Pubitemid 39202302)
3. Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, Anderson JJ, O'Hara C, Finn KT, Libbey CA, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004;140:85-93.
4. Seldin DC, Anderson JJ, Skinner M, Malek K, Wright DG, Quillen K, Finn K, Oran B, Sanchorawala V. Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65. Blood 2006;108:3945-3947. (Pubitemid 44864581)
5. Dey BR, Chung SS, Spitzer TR, Zheng H, Macqillivray TE, Seldin DC, McAfee S, Ballen K, Attar E, Wang T, et al. Cardiac transplantation followed by dose-intensive melphalam and autologous stem-cell transplantation for light-chain amyloidosis and heart failure. Transplantation 2010;90:905-911.
6. Casserly LF, Fadia A, Sanchorawala V, Seldin DC, Wright DG, Skinner M, Dember LM. High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease. Kidney Int 2003;63:1051-1057. (Pubitemid 36315584)
7. McDiarmid S, Hutton B, Atkins H, Bence-Bruckler I, Bredeson C, Sabri E, Huebsch L. Performing allogeneic and autologous hematopoietic SCT in the outpatient setting: effects on infectious complications and early transplant outcomes. Bone Marrow Transplant 2010;45:1220-1226.